Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone

Cancer Immunology, Immunotherapy

Volumn 64, Issue 12, 2015, Pages 1623-1635

  Krug, Christian ^a,d   Birkholz, Katrin ^a   Paulus, Alexander ^a   Schwenkert, Michael ^d   Schmidt, Patrick ^b,c   Hoffmann, Nicole ^b,c   Hombach, Andreas ^b,c   Fey, Georg ^d   Abken, Hinrich ^b,c   Schuler, Gerold ^a   Schuler Thurner, Beatrice ^a   Dörrie, Jan ^a   Schaft, Niels ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adoptive T cell therapy; Chimeric antigen receptor; Melanoma; Melanoma associated chondroitin sulfate proteoglycan (MCSP); mRNA transfection; Single chain variable fragment (scFv)

Indexed keywords

CD28 ANTIGEN; CD3 ZETA ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; MELANOMA ASSOCIATED CHONDROITIN SULFATE PROTEOGLYCAN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MITOCHONDRIAL PROTEIN; SMCP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CELL THERAPY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE PRODUCTION; CYTOLYSIS; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RNA TRANSPORT; SURVIVAL TIME; T LYMPHOCYTE; TRANSIENT TRANSFECTION; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICE; MITOCHONDRIAL PROTEINS; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; SINGLE-CHAIN ANTIBODIES;

EID: 84947026614     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1767-4     Document Type: Article

References (67)

1. Barrett DM, Singh N, Porter DL, Grupp SA, June CH (2014) Chimeric antigen receptor therapy for cancer. Annu Rev Med 65:333–347
2. Biagi E, Marin V, Giordano Attianese GM, Dander E, D’Amico G, Biondi A (2007) Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica 92(3):381–388
3. Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39(1):49–60
4. Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA (2014) Morgan RA (2014) Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer 2:25. doi:10.1186/2051-1426-2-25.eCollection
5. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24(13):e20–e22
6. Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, Oosterwijk E, Sleijfer S, Debets R, Gratama JW (2011) Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117(1):72–82
7. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851
8. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73
9. Almasbak H, Rian E, Hoel HJ, Pule M, Walchli S, Kvalheim G, Gaudernack G, Rasmussen AM (2011) Transiently redirected T cells for adoptive transfer. Cytotherapy 13(5):629–640
10. Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kampgen E, Schuler G, Abken H, Schaft N, Dorrie J (2009) Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther 16(5):596–604
11. Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, Weissman SM (2006) Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 17(10):1027–1035
12. Yoon SH, Lee JM, Cho HI, Kim EK, Kim HS, Park MY, Kim TG (2009) Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther 16(6):489–497
13. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA (2011) Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 22(12):1575–1586
14. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2(2):112–120
15. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1(1):26–31
16. Hombach AA, Schildgen V, Heuser C, Finnern R, Gilham DE, Abken H (2007) T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 178(7):4650–4657
17. Hombach AA, Rappl G, Abken H (2013) Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 “super-stimulation”. Mol Ther 21(12):2268–2277
18. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453–1464
19. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B (2002) Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol 23(5):240–245
20. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H (2001) T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 61(5):1976–1982
21. Wilson BS, Ruberto G, Ferrone S (1983) Immunochemical characterization of a human high molecular weight—melanoma associated antigen identified with monoclonal antibodies. Cancer Immunol Immunother 14(3):196–201
22. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S (2004) Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24(4):267–296
23. Chekenya M, Rooprai HK, Davies D, Levine JM, Butt AM, Pilkington GJ (1999) The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int J Dev Neurosci 17(5–6):421–435
24. Godal A, Bruland O, Haug E, Aas M, Fodstad O (1986) Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells. Br J Cancer 53(6):839–841
25. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, Staugaitis SM (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96(18):10361–10366
26. Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID (1996) Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87(3):1134–1139
27. Ferrone S, Chen ZJ, Liu CC, Hirai S, Kageshita T, Mittelman A (1993) Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. Pharmacol Ther 57(2–3):259–290
28. Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ (1990) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136(6):1393–1405
29. Midwood KS, Salter DM (1998) Expression of NG2/human melanoma proteoglycan in human adult articular chondrocytes. Osteoarthr Cartil 6(5):297–305
30. Tordsson JM, Ohlsson LG, Abrahmsen LB, Karlstrom PJ, Lando PA, Brodin TN (2000) Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Cancer Immunol Immunother 48(12):691–702
31. Petrini S, Tessa A, Carrozzo R, Verardo M, Pierini R, Rizza T, Bertini E (2003) Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Abnormal expression in merosin-negative and Duchenne muscular dystrophies. Mol Cell Neurosci 23(2):219–231
32. Challier JC, Carbillon L, Kacemi A, Vervelle C, Bintein T, Galtier M, Espie MJ, Uzan S (2001) Characterization of first trimester human fetal placental vessels using immunocytochemical markers. Cell Mol Biol (Noisy-le-grand) 47:OL79–OL87
33. Erfurt C, Sun Z, Haendle I, Schuler-Thurner B, Heirman C, Thielemans K, Van Der BP, Schuler G, Schultz ES (2007) Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity. J Immunol 178(12):7703–7709
34. de Vries JE, Keizer GD, te Velde AA, Voordouw A, Ruiter D, Rumke P, Spits H, Figdor CG (1986) Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int J Cancer 38(4):465–473
35. Ozerdem U (2006) Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer. Prostate 66(3):294–304
36. Ozerdem U (2006) Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse. Ophthalmic Res 38(5):251–254
37. Li Y, Wang J, Rizvi SM, Jager MJ, Conway RM, Billson FA, Allen BJ, Madigan MC (2005) In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells. Invest Ophthalmol Vis Sci 46(12):4365–4371
38. Rizvi SM, Qu CF, Song YJ, Raja C, Allen BJ (2005) In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27. Cancer Biol Ther 4(7):763–768
39. Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kugler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dorrie J, Ferrone S, Kampgen E, Fey GH (2008) A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Res 18(2):73–84
40. de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E (2010) Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 9:301. doi:10.1186/1476-4598-9-301
41. Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, Baeuerle PA, Morton DL (2011) Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother 34(8):597–605
42. Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA (2010) A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res 70(8):3027–3033
43. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H (2011) Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA 108(6):2474–2479
44. Kozlowski JM, Hart IR, Fidler IJ, Hanna N (1984) A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 72(4):913–917
45. Cheresh DA, Varki AP, Varki NM, Stallcup WB, Levine J, Reisfeld RA (1984) A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem 259(12):7453–7459
46. Harper JR, Perry SK, Davis RM, Laufer DM (1990) Human neuroectoderm-derived cell line secretes fibronectin that shares the HNK-1/10C5 carbohydrate epitope with neural cell adhesion molecules. J Neurochem 54(2):395–401
47. Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES, Kampgen E, Dieckmann D, Schuler G (2005) Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 174(5):3087–3097
48. Krug C, Wiesinger M, Abken H, Schuler-Thurner B, Schuler G, Dorrie J, Schaft N (2014) A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother 63(10):999–1008
49. Schaft N, Dorrie J, Muller I, Beck V, Baumann S, Schunder T, Kampgen E, Schuler G (2006) A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother 55(9):1132–1141
50. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100(9):3155–3163
51. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167(11):6123–6131
52. Chmielewski M, Hombach AA, Abken H (2011) CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther 18(1):62–72
53. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der BP, Thielemans K (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172(11):6649–6657
54. Morgan AC Jr, Galloway DR, Reisfeld RA (1981) Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1(1):27–36
55. Harper JR, Bumol TF, Reisfeld RA (1982) Serological and biochemical analyses of monoclonal antibodies to human melanoma-associated antigens. Hybridoma 1(4):423–432
56. Winn HJ (1961) Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 86:228–239
57. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70(22):9053–9061
58. Li L, Allen C, Shivakumar R, Peshwa MV (2013) Large volume flow electroporation of mRNA: clinical scale process. Methods Mol Biol 969:127–138
59. Casucci M, Hawkins RE, Dotti G, Bondanza A (2015) Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother 64(1):123–130
60. Hombach A, Hombach AA, Abken H (2010) Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther 17(10):1206–1213
61. Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ Jr (2015) A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget 6(25):21533–21546
62. Hombach A, Abken H (2007) Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. Cancer Immunol Immunother 56(5):731–737
63. Finney HM, Lawson AD, Bebbington CR, Weir AN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161(6):2791–2797
64. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE (2010) The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 184(12):6938–6949
65. Yewdell JW, Anton LC, Bennink JR (1996) Defective ribosomal products (DRiPs): A major source of antigenic peptides for MHC class I molecules? J Immunol 157(5):1823–1826
66. Hofmann C, Hofflin S, Huckelhoven A, Bergmann S, Harrer E, Schuler G, Dorrie J, Schaft N, Harrer T (2011) Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes. Blood 118(19):5174–5177
67. Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257(1):83–90